If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.60
Ask: 13.90
Change: 0.15 (1.10%)
Spread: 0.30 (2.206%)
Open: 13.60
High: 13.75
Low: 13.75
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

Thu, 03rd Mar 2022 19:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based commercial passenger aircraft leasing company - For the six months ended December 31, pretax loss narrows to USD15.9 million from USD60.5 million, due to a much lower impairment loss on aircraft and credit losses. Revenue drops 6% year-on-year to USD57.9 million from USD61.3 million. Avation's aircraft fleet stands at 42, however fleet assets declines 7.0% year-on-year to USD1.00 billion as at December 31 from USD1.08 billion at the end of June.

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - For 2021, pretax profit rises 57% year-on-year to GBP5.8 million from GBP3.7 million the year before, on revenue which grows 17% year-on-year to GBP57.7 million from GBP49.3 million, with double digit sales from Metro Rod and Metro Plumb, as well as a strong recovery from the B2C division. Declares final dividend of 0.9 pence per share, bringing total payout to 1.5p, up 36% from 1.1p. Looking ahead, reports strong start to 2022, with continued sales growth in B2B.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - For the period from incorporation on March 19 to December 31, posts pretax loss of GBP2.3 million and no revenue as the company continues to develop its severe influenza treatment POLB 001.

----------

Crystal Amber Fund Ltd - Guernsey-based investment company - As at December 31, net asset value per share increases 11% year-on-year to 143.19 pence from 128.99p. For the six month period, delivered NAV negative return of 0.8%, compared to a 4.7% positive return from the Numis Small Cap Index.

----------

JPMorgan Global Growth & Income PLC - invests in companies around the world - As at December 31, net asset value per share increases 6.1% year-on-year to 459.1 pence from 432.3p, while for the six month period, NAV total return is 8.2%, compared to a 7.7% return from the MSCI AC World Index.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - For 2021, operating loss widens to USD2.7 million from USD1.8 million, on revenue which declines 16% year-on-year to USD4.2 million from USD5.0 million due to supply chain issues and a performance turnaround only taking place near the end of 2021.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - For the six months ended December 31, pretax profit drops 54% to GBP7.3 million from GBP15.8 million a year before, due to a rise in costs and a 10% year-on-year decline in revenue to GBP48.7 million from GBP54.0 million, due to the strategic streamlining of older products. Looking ahead, company has a strong outlook for the full financial year with operating profit on track to meet consensus expectations.

----------

Power Metal Resources PLC - London-based metals exploration company focused in North America, Africa and Australia - For the year ended September 30, pretax loss narrows to GBP623,000 from GBP1.4 million the year before, due to smaller impairment charges, and a slight rise in revenue to GBP37,000 from GBP9,000

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.